- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Lexeo Therapeutics GAAP EPS of -$0.33 beats by $0.24 | 3 | Seeking Alpha | ||
| 05.11. | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | 199 | GlobeNewswire (Europe) | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| 05.11. | Lexeo Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.11. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Lexeo Therapeutics raises $153.8 million in public offering | 4 | Investing.com | ||
| 20.10. | Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering | 1 | GlobeNewswire (USA) | ||
| 17.10. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.10. | Stifel lowers Lexeo Therapeutics stock price target to $18 on offering | 5 | Investing.com | ||
| 17.10. | Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 | 4 | Insider Monkey | ||
| 17.10. | Lexeo Therapeutics prices $135M public offering and private placement | 2 | Seeking Alpha | ||
| 17.10. | Lexeo Therapeutics platziert Aktien und Optionsscheine im Wert von 135 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 17.10. | Lexeo Therapeutics prices $135 million public offering and placement | 2 | Investing.com | ||
| 17.10. | Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 16.10. | Lexeo Therapeutics launches stock and warrant offering | 1 | Seeking Alpha | ||
| 16.10. | Lexeo Therapeutics announces public offering and private placement | 1 | Investing.com | ||
| 16.10. | Lexeo Therapeutics stock falls after announcing public offering | 1 | Investing.com | ||
| 16.10. | Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 08.10. | H.C. Wainwright raises Lexeo Therapeutics stock price target to $15 on FDA feedback | 1 | Investing.com | ||
| 07.10. | Lexeo says FDA open to speedier approval of rare disease gene therapy | 3 | BioPharma Dive |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,386 | +1,42 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,630 | +1,88 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| REPLIMUNE | 7,700 | -0,65 % | Cantor Fitzgerald bestätigt "Overweight"-Rating für Replimune nach neuem PDUFA-Termin | ||
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 5,745 | 0,00 % | Quanterix Corp Q3 Loss Increases, Misses Estimates | ||
| BELITE BIO | 99,00 | +1,02 % | Belite Bio outlines regulatory path and $275.6M cash position while preparing for Tinlarebant commercialization | ||
| COGENT BIOSCIENCES | 33,540 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 40,850 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| NUVALENT | 96,50 | 0,00 % | Nuvalent kündigt Präsentation zulassungsrelevanter Daten für Lungenkrebs-Wirkstoff an | ||
| AVIDITY BIOSCIENCES | 70,80 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| INVIVYD | 2,345 | 0,00 % | Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights | PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,135 | 0,00 % | Change at the top of Recursion as co-founder leaves CEO role | ||
| ARCUTIS BIOTHERAPEUTICS | 25,070 | 0,00 % | Arcutis completes enrollment in infant atopic dermatitis study |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.